2023年5月16日

Anavo疗法——一个全球领先的打开人类磷酸酶生物学治疗的潜力——最近宣布一个€850万种子圆形扩展,增加推广投资基金作为一种新的投资者。和所有现有投资者,M公司、INKEF Taiho Ventures和Bioqube企业,参与了扩展,使总种子€2800万。与资金,卡琳Kleinhans,推广企业基金的合伙人将加入现有的董事会,其中包括查尔斯·麦克德莫特(主席);Therese玛丽亚列支敦士登,M公司;西蒙实现INKEF资本;浅沼的荣,Taiho企业;黛博拉杜蒙特Bioqube企业;和Birgit泽赫,Anavo疗法。Anavo疗法被称为第一家系统药物磷酸酶,这是一个丰富的目标空间无药可治之前考虑了几十年。该公司吸引了世界领先的科学技术phosphatase-driven疾病生物学和药物发现解锁phosphatase-targeted全部潜能的变构调节器。 In oncology, Anavo has been developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. KEY QUOTES: “Since our inception in 2021, Anavo Therapeutics has advanced multiple proprietary pipeline programs in this centrally important target class and added significant expertise to the team, SAB, and the board. Today, we welcome MRL Ventures Fund to our existing investor syndicate. Leveraging our unique IGNITE phosphatase drug discovery platform, we will continue to accelerate our proprietary portfolio of programs targeting disease-relevant phosphatases toward clinical development, while continuing to build a center of excellence for phosphatase targeting.” — Birgit Zech, PhD, Chief Executive Officer of Anavo Therapeutics “We are encouraged by the progress being made at Anavo in establishing a systematic approach to phosphatase drug discovery. At MRL Ventures we believe Anavo’s platform offers the potential to harness the therapeutic opportunity of this important target class.” — Karin Kleinhans, PhD, Partner at MRL Ventures Fund Trending on Pulse 2.0